SCHEMBL5223016

SCHEMBL5223016

COC(=O)CN1CCN(Cc2ccc(-c3ccc(-c4noc(C)n4)cc3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.47
LMNA P02545 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
HSD17B10 Q99714 1/20 0.47
KCNH2 Q12809 2/20 0.47
GPR119 Q8TDV5 1/20 0.47
HTT P42858 5/20 0.47
CYP2D6 P10635 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PLK1 P53350 1/20 0.46
MAPK1 P28482 2/20 0.46
USP2 O75604 1/20 0.45
CHKA P35790 1/20 0.45
S1PR1 P21453 2/20 0.44
S1PR4 O95977 1/20 0.44
S1PR5 Q9H228 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225958 0.81 SMN1; SMN2 (0.59) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5225149 0.80 SMN1; SMN2 (0.61) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5223197 0.79 SMN1; SMN2 (0.53) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL5224880 0.78 SMN1; SMN2 (0.62) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL7070548 0.78 MGLL (0.56) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL7129860 0.78 GPR119 (0.61) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL7073968 0.78 MAPT (0.50) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL7655650 0.78 PLK1 (0.57) TSHRLMNASMN1; SMN2ALDH1A1HTT
SCHEMBL28957460 0.78 SMN1; SMN2 (0.63) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL7070577 0.76 SMN1; SMN2 (0.52) TSHRLMNASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP claimed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO claimed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US claimed
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP disclosed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO disclosed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019998-A1 Histamine-3 receptor antagonist HRH3, HRH4, HRH2 TSHR 432/4885LMNA 4508/4885SMN1; SMN2 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.